Thrombocytopenia is a very frequent disorder in the intensive care unit. Many etiologies should be searched, and therapeutic approaches differ according to these different causes. However, no guideline exists regarding optimum practices for these situations in critically ill patients. We present recommendations for the management of thrombocytopenia in intensive care unit, excluding pregnancy, developed by an expert group of the French-Language Society of Intensive Care (Société de Réanimation de Langue Française (SRLF), the French Language Group of Paediatric Intensive Care and Emergencies (GFRUP) and of the Haemostasis and Thrombosis Study Group (GEHT) of the French Society of Haematology (SFH). The recommendations cover six fields of application: definition, epidemiology, and prognosis; diagnostic approach; therapeutic aspects; thrombocytopenia and sepsis; iatrogenic thrombocytopenia, with a special focus on heparin-induced thrombocytopenia; and thrombotic microangiopathy.
Introduction and presentation of the expert recommendations of the French-language Intensive Care Society (Société de Réanimation de Langue Française (SRLF)) Thrombocytopenia is the hemostatic disorder that is most frequently encountered in intensive care and is seen in 41-66% of patients (close to 50% at admission). In view of the mortality associated with thrombocytopenia, the numerous associated pathological conditions seen in intensive care, and the lack of recommended treatment strategy, the SRLF has drawn up these recommendations.
An SRLF expert group drew up recommendations, giving reasoned arguments for each of six fields of application defined by the organizing committee, including pediatric specificities. Each expert (or expert subgroup) then presented and justified the content and form of the proposed recommendations, changes to which could be made during the ensuing discussion. The revised recommendations were then put to the vote. The purpose was not to impose a single expert point of view for all the recommendations but to delineate clearly the points of agreement that underpin the recommendations, as well as points of disagreement or indecision that may form the basis of future work.
Recommendations were scored according to an approach based on the RAND/UCLA Appropriateness Method. After the first round of voting for each recommendation (score 1 for complete disagreement or lack of any proof to 9 for complete agreement or conclusive evidence), the highest and lowest scores were eliminated, and the score was taken as the median of the remaining scores. The upper and lower bounds were then considered as "strong agreement" if they lay within the range 7-9 and "strong disagreement" in the range 1-3. Such scores were considered definitive. Recommendations whose scores were not within these two ranges were voted on again, following the same principle. After this second round of voting, the scores were taken as follows:
-Median and bounds within range [7-9] = "strong agreement" -Median and bounds within range [1] [2] [3] = "strong disagreement" -Median within range [7-9] with lower bound < 7 = "weak agreement" -Median within range [1] [2] [3] with upper bound > 3 = "weak disagreement" -Median within range [4-6] = "uncertainty"
The methodology used was inspired by the GRADE system (Grading of Recommendations Assessment, Development and Evaluation) for rating clinical guidelines (http://www.gradeworkinggroup.org/links.htm), the originality of which stems primarily from three assertions. First, characterization of the type of study alone (e.g., randomized or not) is insufficient to indicate the level of proof of a study. Second, the risk/benefit ratio is taken into account. Third, the exact wording of guidelines carries clear implications for users: "should be done/ recommended. . ." (strong agreement) or "should not be done/not recommended" (strong disagreement), "should probably be done/is possible" (weak agreement), or "should probably not be done/is possible not to do" (weak disagreement).
Field 1: Definition -epidemiology -prognosis 1. Thrombocytopenia is defined by a platelet count (PC) < 150 × 10 9 /L (strong agreement). 2. In intensive care, pseudothrombocytopenia should be discounted using in vitro agglutination of platelets, by preparing a blood film, or, if necessary, using a blood sample collected in a citrate tube (strong agreement). 3. An etiological investigation is required to determine the causes and underlying mechanisms of a PC < 100 × 10 9 /L or a > 30% decrease in PC. It also can be done for a drop in PC, independently of these cutoffs, depending on the pathological context (strong agreement). 4. A more than 30% drop in PC should probably be considered to be associated with a poor prognosis (weak agreement). 5. Changes in PC over time (duration, speed of decrease or rise, etc.) should be considered to be associated with the prognosis (strong agreement). 
Heparin-induced thrombocytopenia
47. Whichever heparin is used (UFH or LMWH), baseline PC should be measured on initiation or during the first 24 hours of treatment (strong agreement). 48. PC should probably be measured twice in any patient exposed to UFH during the past 3 months, first upon initiation of heparin therapy (UFH or LMWH) and then the next day (weak agreement). 49. In intensive care, PC should be measured twice a week during the first 3 weeks of heparin therapy (UFH or LMWH)(strong agreement). 50. Warkentin 4-T score should be used to assess the probability of HIT, even though it has not been specifically validated in intensive care (see Additional file 3) (strong agreement). 51. In patients with a Warkentin 4-T score < 2, a laboratory test of HIT should probably not be done (weak agreement). 52. Two types of diagnostic laboratory tests should probably be combined in any patient with suspected HIT: one functional and one immunoenzymatic (ELISA) to screen for antiheparin PF4 antibodies (weak agreement). 53. Heparin should be excluded if there is a history of HIT. A nonheparin anticoagulant is recommended (strong agreement). 54. If there is a history of HIT, danaparoid is the first-line anticoagulant in intensive care (strong agreement). 55. In a patient with suspected HIT and a Warkentin 4-T score ≥ 2, withdrawal of heparin should probably be considered (weak agreement). 56. In a patient with suspected HIT and a Warkentin 4-T score ≥ 4, heparin should be replaced immediately by an empirical nonheparin treatment at curative dosage: danaparoid sodium, lepirudin, or even bivalirudin (strong agreement). 57. In intensive care, fondaparinux is probably not recommended as replacement therapy during the acute phase of HIT (weak agreement). 58. In intensive care, the introduction of vitamin K antagonists during the acute phase of HIT is contraindicated (strong agreement).
Field 6: Thrombotic microangiopathy 59. Thrombocytopenia associated with mechanical hemolytic anemia should suggest TMA, even in the absence of organ failure (strong agreement). 60. In any patient with suspected TMA, the blood samples (2 dry tubes and 2 EDTA tubes) for etiological investigation (ADAMTS13 activity, complement, autoimmunity, HIV) should be collected before any treatment, without delaying its initiation (strong agreement). 61. The first-line treatment of TMA should be based on emergency plasma exchange (PE) (rate 60 mL/kg). If PE is not initially possible, plasma should be infused at 20 mL/kg when possible (strong agreement). 62. In TMA, PE should be continued daily for at least 5 to 7 days until the PC normalizes and is stable for at least 48 hours. The rate of PE is lowered progressively, on a case-by-case basis (strong agreement). 63. In adults and children with TMA, platelet transfusion is strictly contraindicated unless there is life-threatening bleeding (strong agreement). 64. In adults with TMA, an invasive procedure is not an indication for routine prophylactic platelet transfusion because of potentially lethal adverse effects (strong agreement 
